This mechanism not only explains the beneficial effect of metformin in CRC prevention, but also provides additional molecular insight into why high MYC‐expressing cancer cells, which are usually ‘addicted’ to MYC, are more sensitive to metformin treatment (Javeshghani et al., 2012). The gene discussed is MYC; the disease is cancer.